Biotech Values

[dewophile]

zgen
i am guessing atacicept has been all but written off in most valuation models gien the current market cap. Thomas (seemingly precient now) mentioned early last year that IN lambda was the wild card for ZGEN. In 2010 when most of the atacicept data emerges that candidate could be the next wild card given they maintained a relatively high royalty (low double digits ex-US and if i recall mid to upper teens in the US)